Aditxt Inc. Signs Share Exchange Agreement to Acquire AiPharma Global Holdings LLC

BiomX Acquires Adaptive Phage Therapeutics

March 18, 2024

Biotechnology

BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.

Pfizer Acquires Amplyx Pharmaceuticals

April 28, 2021

Biotechnology

Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.

Aditxt, Inc. Acquires Evofem Biosciences, Inc.

December 12, 2023

Biotechnology

Aditxt, Inc. has entered into a definitive agreement to acquire Evofem Biosciences in a stock-and-debt assumption transaction that will make Evofem a wholly owned subsidiary of Aditxt pending closing (anticipated H1 2024). The deal transfers approximately $100 million of consideration via stock issuance and assumption of certain senior indebtedness, and positions Aditxt to establish a women's health mission and scale Evofem’s hormone-free contraceptive Phexxi and other women's health products globally.

Pfizer's Hospital Business Acquires Arixa Pharmaceuticals

October 22, 2020

Pharmaceuticals

Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.